A Phase I Study of Donor BPX-501 T Cell Infusion for Adults with
Recurrent or Minimal Residual Disease Hematologic Malignancies
Post-Allogeneic Transplant

Principal Investigator

Richard Maziarz

Study Purpose

This research study will test whether immune cells, called T cells, when grown in a lab and then transplanted, can help the immune system recover faster and kill tumor cells.

In addition, this study will evaluate the safety of the infusion of escalating doses of the drug Rimiducid.

Medical Condition(s)

Myelodysplastic Syndromes
Multiple myeloma
Other high-risk hematologic malignancies eligible for stem cell transplantation

Eligibility Criteria

This study accepts the following diseases: Leukemia, Myelodysplastic Syndromes, Lymphomas, Multiple myeloma, other high-risk hematologic malignancies eligible for stem cell transplantation. One of the aforementioned diseases must be present and evidence of recurrent disease that presents more than 100 days post-transplant, or minimal residual disease (MRD) that presents more than 30 days after matched or mismatched related Hematopoietic stem cell transplantation (HSCT) must also be present.

Age Range

18 - 65

Healthy Volunteers Needed


Duration of Participation

The treatment phase of the study is expected to last at least 60 days. After the first year participants will be asked to return to the clinic every 3 months until 2 years after the first infusion, then annually to year 5, then for 10 more years for a total of 15 years after the first infusion.

Minors Included



Knight Cancer Intake Center: (503)494-7999
Clinical Trials Information Line: (503)­494-­1080 or


Bellicum Pharmaceuticals, Inc.

Recruitment End


Compensation Provided


Go Back